Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Prepaid Assets (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Prepaid Assets readings, the most recent being $6054.0 for Q4 2025.

  • Quarterly Prepaid Assets rose 66.32% to $6054.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6054.0 through Dec 2025, up 66.32% year-over-year, with the annual reading at $6054.0 for FY2025, 66.32% up from the prior year.
  • Prepaid Assets hit $6054.0 in Q4 2025 for Drugs Made In America Acquisition, down from $27479.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $70096.0 in Q1 2025 and bottomed at $3640.0 in Q4 2024.